Industry Detail

Market Outline:

The Obesity Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.

Obesity has been categorized into different types, its classification varies depending upon the country guidelines and regional diagnosis. Majority of the countries follow WHO based clinical guidelines and few adopted the country based classification.

Disease Burden Analysis:

• In Brazil, the projected prevalence of obesity is estimated to be 33% for women and 25% for men by 2030
• According to National Health Survey conducted by IBGE nearly 26 million people are obese.
• Significant jumps observed in the overall prevalence of obesity from 11.86%-21.76% from 2006-2023
• Nearly 700-800 Million people suffering from Obesity globally. Due to substantial change in life style modification, one in every three person is suffering from obesity as per recent statistics
• According to WHO it is estimated that, by 2030 it is predicted that 1 in 5 women and 1 in 7 men will be living with obesity (BMI ≥30kg/m2 ), equating to over 1 billion people globally.
• Global prevalence of obesity is higher amongst women than men, highlighting the need for inclusive policies based on lived experience.

Over half the population in OECD countries is overweight, with nearly 1 in 4 people considered obese. In the next 30 years, this will cause 220 million cases of noncommunicable diseases (NCDs) in OECD countries.

Report Insights:

• In Brazil treatment rate reported merely 10%-12%
• Factors responsible for driving obesity in Brazil are increased fast food consumption, decreased physical activity and remote working.
• More than 1500 clinical trials, United States is the dominated region
• Huge unmet need exists
• Gaps in Country Policies Identified ate every level 
• >50 pipeline assets about to witness the market by 2040
• Opportunity worth of USD 70 billion is expected to roll out in the market
• The World Obesity Atlas estimates that the total costs attached to obesity – both healthcare and productivity related – will exceed $4 trillion worldwide by 2035
• Market largely dominated by off-label drugs, Report has analysed the key drugs penetrating as off-label.
• CSP Analytics Solutions provided the clinical mapping of key pipeline molecules

The Brazil and Mexico Obesity Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR 6.21% over the projected period. And by 2033, the market is expected to touch USD XX Million.

Market Segmentation Analysis by:

• By Treatment Mode:
  • Prescription
  • Off-Label
• By Therapy:
  • Saxenda (liraglutide)
  • Victoza (liraglutide)
  • Liraglutide biosimilar
  • Wegovy (semaglutide)
  • Ozempic (semaglutide) 
  • Others
• By End User:
  • Hospitals
  • Clinics
  • Others

Market Dynamics: Explored in report

• Surging Prevalence of Obesity Across Region
• Growing Clinical Trial Activities 
• Huge Market Unmet Need
• Rising drug Penetration in Obesity Segment

Market Challenges: Explored in report

• Lack of Efficacious Treatment Option
• Cost of Treatment
• Off-Label Drug Usages
• Underdiagnoses in Emerging Market
• Substitution of Products

Regional Outlook: 

Report has fragmented the total market in five regions such as Brazil and Mexico

Each mapped region has been examined at granular level based on certain parameters:

• Brazil
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• Mexico
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)

Competitive Landscape: Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Companies Profile:

• Eli Lilly
• Novo Nordisk
• Pfizer
• Boehringer Ingelheim
• Zealand Pharma
• OPKO Health
• Versanis Bio Inc.
• Rhythm Pharmaceuticals
• Roche
• Orexigen Therapeutics
• H2-Pharma
• Chelapharm
• Vivus Inc.
• Aphaia Pharma US LLC
• Currax Pharmaceuticals
• NGM Biopharmaceuticals, Inc
• Guangdong Raynovent Biotech Co., Ltd
• Rhythm Pharmaceuticals, Inc.
• FUJIFILM Toyama Chemical Co Ltd
• Others

Pipeline molecules investigated in the report: